European Commission approves extended Libtayo dosing interval across existing cancer indications

The European Commission has approved a longer dosing interval for Regeneron's Libtayo across its existing authorised cancer indications, offering an alternative administration schedule without expanding the medicine's approved disease indications.
Regeneron announced on 17 November 2026 that the European Commission had authorised an alternative dosing regimen for Libtayo (cemiplimab) across its existing approved skin, lung and cervical cancer indications, allowing eligible patients to receive 700 mg intravenously every six weeks after an initial 12 weeks of 350 mg every three weeks.
The decision also permits shorter infusion times for selected 350 mg doses following a well-tolerated initial infusion, potentially reducing treatment visits and administration burden; this is an EU dosing and administration update rather than approval for a new cancer indication, while the corresponding US supplemental application remains under FDA review.
Field | Content |
Company | Regeneron |
Medicine | Libtayo (cemiplimab) |
Regulatory Authority | European Commission |
Approval Date | 17 November 2026 |
Approval Type | Alternative dosing and administration authorisation |
Therapeutic Area | Oncology |
Existing Indication Areas | Authorised skin lung and cervical cancer indications |
Initial Dosing | 350 mg intravenously every three weeks |
Initial Dosing Duration | 12 weeks |
Alternative Maintenance Dose | 700 mg intravenously |
Alternative Dosing Interval | Every six weeks |
Administration Update | Shorter infusion times permitted for selected 350 mg doses following a well-tolerated initial infusion |
New Cancer Indication | No |
Potential Patient Benefit | Fewer infusion visits and reduced administration burden for eligible patients |
EU Regulatory Status | Approved alternative regimen |
US Regulatory Status | Corresponding supplemental application under FDA review |
Primary Source | https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-union-eu-extended-dosing/ |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Kommentare